1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Global Irritable Bowel Syndrome Treatment Market Research Report Forecast to 2023

Global Irritable Bowel Syndrome Treatment Market Research Report Forecast to 2023

  • March 2019
  • 105 pages
  • ID: 5774392
  • Format: PDF
  • By Market Research Future

Summary

Table of Contents

Search Inside

Introduction

Irritable bowel syndrome (IBS) is a global issue, with 5% to 15% of the total population experiencing symptoms that would satisfy the definition of IBS. This condition is characterized by stomach pain and distress with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical clarification for these symptoms. The growing prevalence of anxiety, strong drug pipeline, and increasing prevalence of depression are expected to drive the market growth. In a systematic review of the global prevalence of IBS, in 2015 Lovell and Ford documented a collective prevalence of 11% with all regions of the world anguishing from this disorder at parallel rates. However, stringent government regulations and limited patient satisfaction with IBS treatment provided by healthcare professionals may hamper the growth of the market.
The global irritable bowel syndrome treatment market is expected to reach a market value of USD 2,988.6 million by 2023 from USD 1,890.9 million in 2017 and is expected to register a CAGR of 7.58% during the forecast period from 2018 to 2023. In 2016, the Americas held the highest share of the market at 45%, followed by Europe and Asia-Pacific with shares of 29% and 18%, respectively. Growing prevalence of IBS worldwide is expected to increase the growth of the market during the forecast period.
The global irritable bowel syndrome treatment market is segmented into type, drug type, end user, and region.
The global irritable bowel syndrome treatment market, by type, is segmented into IBS-D, IBS-C, and IBS-M.
The global irritable bowel syndrome treatment market, by drug type, is segmented into lubiprostone, linaclotide, eluxadoline, rifaximlin, alosetron, and others.
By end user, the global irritable bowel syndrome treatment market is segmented into hospitals, clinics, research laboratories, and others.

Key Players

Abbott, Allergan Inc., Ardelyx, Inc., Astellas Pharma, Inc., Ironwood Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Mallinckrodt, Nestle Health Science, Synergy Pharmaceuticals Inc., and Valeant Pharmaceuticals International, Inc.

Study Objectives

• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the irritable bowel syndrome treatment market
• To provide insights into factors affecting the market growth
• To analyze the global irritable bowel syndrome treatment market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by type, drug type, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the irritable bowel syndrome treatment market

Target Audience

• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Research and Development (R&D) Companies
• Government Research Laboratories
Key Findings
• The global irritable bowel syndrome treatment market is expected to reach USD 2,988.6 million by 2023 at a CAGR of 7.58% from 2018 to 2023
• On the basis of type, the IBS-D segment accounted for the largest market share at a CAGR of 8.31%
• On the basis of drug type, the linaclotide segment accounted for the largest market share at a CAGR of 7.95%
• On the basis of end user, the hospitals segment accounted for the largest market share at a CAGR of 8.04%
• The Americas is expected to hold the largest share of the global irritable bowel syndrome treatment market at a CAGR of 8.69% by 2023
• Europe is the second largest market, which is expected to register a CAGR of 7.31% by 2023

Regional Analysis

• Americas
o North America
US
Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Companies Mentioned

Abbott
Allergan Inc.
Ardelyx, Inc.
Astellas Pharma, Inc.
Ironwood Pharmaceuticals
Lexicon Pharmaceuticals, Inc.
Mallinckrodt
Nestle Health Science
Synergy Pharmaceuticals Inc.
Valeant Pharmaceuticals International, Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019, provides ...

Constipation - Pipeline Review, H2 2019

Constipation - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Constipation - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) ...

Reflux Esophagitis - Pipeline Review, H2 2019

Reflux Esophagitis - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Reflux Esophagitis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides an overview of the Reflux Esophagitis ...

Consumer Health in Jordan $ 2100 October 2019

Consumer Health in Lebanon $ 2100 October 2019

Consumer Health in Australia $ 2650 October 2019

Consumer Health in Ethiopia $ 2100 October 2019

Consumer Health in Qatar $ 2100 October 2019

Consumer Health in China $ 2650 October 2019


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on